Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 374 M
EBIT 2017 -14,1 M
Net income 2017 -50,9 M
Finance 2017 186 M
Yield 2017 -
Sales 2018 461 M
EBIT 2018 -18,0 M
Net income 2018 -49,3 M
Finance 2018 110 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 14,9x
EV / Sales2018 12,2x
Capitalization 5 750 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery.It operates its business through the Ionis Core and Akea Therapeutics segments.The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.The Akea... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
05/25 IONIS PHARMACEUTICALS : Announces Phase 3 NEURO-TTR Study of Inotersen IONIS-TTR..
05/25 IONIS PHARMACEUTICALS : Akcea Announces Publication in The New England Journal o..
05/18 IONIS PHARMACEUTICALS, INC. (NASDAQ : IONS) Files An 8-K Other Events
05/18 IONIS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
05/16 IONIS PHARMACEUTICALS : Announces Phase 3 Results for Inotersen
05/16 IONIS PHARMACEUTICALS INC : Blog Coverage: Ionis Pharma Reported Positive Phase ..
05/16 IONIS PHARMACEUTICALS : shares fall on clinical trial death, but trial succeeds
05/15 IONIS PHARMACEUTICALS : Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TT..
05/11 IONIS PHARMACEUTICALS : Provides Corporate Update at 2017 Annual Meeting of Stoc..
05/10 IONIS PHARMACEUTICALS : to Present at Bank of America Merrill Lynch 2017 Healthc..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 45,2 $
Spread / Average Target -2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%5 750
INCYTE CORPORATION34.02%27 518
QUINTILES IMS HOLDINGS..13.11%18 565
LONZA GROUP AG25.78%15 571
CELLTRION, INC.--.--%10 213
SEATTLE GENETICS, INC.24.26%9 358
More Results